Zoetis Inc
$ 79.57
-2.25%
12 Jun - close price
- Market Cap 33,357,982,000 USD
- Current Price $ 79.57
- High / Low $ 82.40 / 79.17
- Stock P/E 13.04
- Book Value 7.84
- EPS 6.10
- Next Earning Report 2026-08-04
- Dividend Per Share $2.03
- Dividend Yield 2.49 %
- Next Dividend Date 2026-09-01
- ROA 0.16 %
- ROE 0.68 %
- 52 Week High 164.22
- 52 Week Low 72.38
About
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Analyst Target Price
$124.59
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-12 | 2025-11-04 | 2025-08-05 | 2025-05-06 | 2025-02-13 | 2024-11-04 | 2024-08-06 | 2024-05-02 | 2024-02-13 | 2023-11-02 | 2023-08-08 |
| Reported EPS | 1.42 | 1.48 | 1.7 | 1.61 | 1.48 | 1.4 | 1.58 | 1.56 | 1.31 | 1.24 | 1.36 | 1.41 |
| Estimated EPS | 1.54 | 1.4 | 1.62 | 1.52 | 1.4 | 1.36 | 1.46 | 1.48 | 1.27 | 1.32 | 1.36 | 1.31 |
| Surprise | -0.12 | 0.08 | 0.08 | 0.09 | 0.08 | 0.04 | 0.12 | 0.08 | 0.04 | -0.08 | 0 | 0.1 |
| Surprise Percentage | -7.7922% | 5.7143% | 4.9383% | 5.9211% | 5.7143% | 2.9412% | 8.2192% | 5.4054% | 3.1496% | -6.0606% | 0% | 7.6336% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 1.85 |
| Currency | USD |
Previous Dividend Records
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-06-02 | 2026-03-03 | 2025-12-02 | 2025-09-03 | 2025-06-03 | 2025-03-04 | 2024-12-03 | 2024-09-04 | 2024-06-04 | 2024-03-01 |
| Amount | $0.53 | $0.53 | $0.5 | $0.5 | $0.5 | $0.5 | $0.432 | $0.432 | $0.432 | $0.432 |
Next Dividend Records
| Dividend per share (year): | $2.03 |
| Dividend Yield | 2.49% |
| Next Dividend Date | 2026-09-01 |
| Ex-Dividend Date | 2026-07-20 |
Recent News: ZTS
2026-06-13 02:08:46
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Zoetis, Inc. on behalf of investors who purchased securities between January 14, 2025, and May 6, 2026. The lawsuit alleges that Zoetis made false and misleading statements, failing to disclose weakening prescription growth for Librela, market share loss for Simparica Trio, and competition impacting dermatology products. Investors suffering losses are encouraged to contact the firm before the July 27, 2026, deadline to apply for lead plaintiff.
2026-06-12 19:46:33
Glancy Prongay Wolke & Rotter LLP has announced a securities fraud class action lawsuit against Zoetis Inc. (NYSE: ZTS). The lawsuit, with a lead plaintiff deadline of July 27, 2026, alleges that Zoetis made materially misleading statements regarding the performance of its key products, including Librela, Simparica Trio, Apoquel, and Cytopoint, due to weakening growth, market share loss, and safety concerns. Shareholders who suffered losses on their Zoetis investments are invited to contact the law firm to learn more about participating in the lawsuit.
2026-06-12 16:32:00
The Gross Law Firm has issued a shareholder alert for Zoetis Inc. (NYSE: ZTS), announcing a securities class action lawsuit. The complaint alleges that Zoetis made misleading statements and failed to disclose critical information regarding its products, including weakening prescription growth for Librela due to FDA safety warnings, loss of market share for Simparica Trio, and substantial market share loss for Apoquel and Cytopoint. Shareholders who purchased ZTS shares between January 14, 2025, and May 6, 2026, are encouraged to contact the law firm, with a lead plaintiff deadline of July 27, 2026.
2026-06-12 16:27:43
Bragar Eagel & Squire, P.C. has announced that a class action lawsuit has been filed against Zoetis, Inc. (NYSE:ZTS) on behalf of investors who purchased securities between January 14, 2025, and May 6, 2026. The lawsuit alleges that Zoetis made misleading statements and failed to disclose issues regarding weakening prescription growth for its canine pain treatment Librela, loss of market share for Simparica Trio, and substantial market share loss for its dermatology products due to competing treatments. Investors who suffered losses are encouraged to contact the firm before the July 27, 2026 deadline to apply for lead plaintiff.
2026-06-12 16:08:40
The Gross Law Firm has issued a shareholder alert for Zoetis Inc. (NYSE: ZTS) investors, announcing a securities class action lawsuit. The lawsuit alleges that Zoetis made false or misleading statements regarding weakening veterinarian prescription growth for Librela, market share loss for Simparica Trio, and substantial market share loss for its dermatology products Apoquel and Cytopoint. Shareholders who purchased ZTS shares between January 14, 2025, and May 6, 2026, are encouraged to contact the firm, with a lead plaintiff deadline of July 27, 2026.
2026-06-12 14:08:51
The Schall Law Firm is reminding investors of a class action lawsuit against Zoetis Inc. (NYSE: ZTS) for alleged securities fraud. The lawsuit claims that Zoetis made false and misleading statements about its products, including weakening prescription growth for Librela, market share loss for Trio, and competition for Apoquel and Cytopoint. Investors who purchased securities between January 14, 2025, and May 6, 2026, are encouraged to contact the firm before July 27, 2026, to discuss their rights.
